reports
Santalis Pharmaceuticals Announces Notice of Allowance of a US Patent ...
SAN ANTONIO--(BUSINESS WIRE)-- Santalis Pharmaceuticals, Inc. announced today the Notice of Allowance by the United States Patent Office of a patent containing nine claims covering the use of East Indian sandalwood (Santalum album) oil-containing compositions to treat Clostridium infections including Clostridium difficile (C. diff). This will be the first patent issued to Santalis Pharmaceuticals for the use of sandalwood oil to treat infectious disease. Clostridium difficile infection (CDI) is a potentially-fatal infe...
Ford Equity International Rating and Forecast Report
Ford Equity International Research Reports cover 60 countries with over 30,000 stocks traded on international exchanges. A proprietary quantitative system compares each company to its peers on proven measures of business value, growth characteristics, and investor behavior. Ford's three recommendation ratings buy, hold and sell, represent each stock’s return potential relative to its own country market.. The rating reports which are generated each week, include the fundamental details behind...
Supportive Data for the Use of Santalis Pharmaceuticals’ East Indian...
SAN ANTONIO--(BUSINESS WIRE)-- Data supporting the use of East Indian sandalwood oil (EISO) for the treatment of psoriasis was presented by Dr. Manju Sharma, of the Vancouver Prostate Centre, at the recent 7th Euro-Global Summit on Toxicology and Applied Toxicology held in Rome, Italy on 24 October, 2016. Dr. Sharma examined the ability of EISO to impact the psoriatic phenotype using organotypic psoriasis tissue and normal (non-psoriatic) human skin models. Treatment of the psoriasis tissue model with EISO reverted psoriatic pathology...
Santalis Pharmaceuticals Obtains FDA Allowance To Start A Phase 2 Clin...
SAN ANTONIO--(BUSINESS WIRE)-- Following the recent start of its pediatric and adult Phase 2 clinical study for atopic dermatitis in Australia, Santalis Pharmaceuticals today announced it has obtained allowance from the U.S. Food and Drug Administration (FDA) to initiate a multi-center, placebo controlled, double blinded, Phase 2 efficacy and tolerability study for the treatment of mild to moderate atopic dermatitis (AD), also known as eczema. Patients must be 17 years of age or older with a clinically stable diagnosis of atopic derma...
Santalis Pharmaceuticals Announces Issuance of Patent for the Use of S...
SAN ANTONIO--(BUSINESS WIRE)-- Santalis Pharmaceuticals, Inc. announced today the issuance by the Japanese Patent Office of a patent that covers sandalwood oil-containing compositions that can be used to treat a variety of cancers. The patent for invention number 5,972,797 includes claims that protect compositions for treatment of solid tumors, including bladder cancer, and also covers preventing the progression of actinic keratoses (AK) to squamous cell carcinoma (SCC). According to Dr. Paul Castella, CEO of Santalis Pharmac...
Insider bought: A director bought 64,000 shares at 1.563AUD
A director at TFS Corporation Limited bought 64,000 shares at 1.563AUD and the significance rating of the trade was 51/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two ...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.